AI-Powered Clinical Decision Support Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 0.87 Billion |
| Market Size (2030) | USD 1.79 Billion |
| CAGR (2025 - 2030) | 15.60% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
AI-Powered Clinical Decision Support Market Analysis
The AI-Powered Clinical Decision Support Market size is estimated at USD 0.87 billion in 2025, and is expected to reach USD 1.79 billion by 2030, at a CAGR of 15.6% during the forecast period (2025-2030).
Factors such as the technological advancements in healthcare IT across facilities, the need to enhance the quality of care and minimize human errors, and the rising demand to reduce healthcare expenditure are expected to boost the market's growth during the forecast period.
Various studies have evaluated the potential of artificial intelligence in healthcare settings. For instance, a March 2024 article in the European Journal of Health, Psychology, and Education highlighted that Artificial Intelligence Clinical Decision Support Systems (AI-CDSSs) could significantly benefit primary healthcare (PHC) activities, aiding in diagnosis, patient management, and preventive measures. Furthermore, the integration of AI-CDSSs across healthcare facilities has successfully minimized prescription errors without inducing alert fatigue. With AI-enhanced CDSSs, electronic health records (EHRs) are now better equipped for clinical reasoning, managing larger volumes of information with a more holistic approach. Thus, the benefits offered by AI-powered CDS systems are expected to increase their adoption across healthcare facilities, boosting the market's growth.
Artificial intelligence-driven clinical decision support systems (CDSSs) enhance patient care by equipping healthcare professionals with precise and tailored insights for risk assessment, diagnosis, treatment optimization, and early monitoring of cardiovascular diseases (CVD). For instance, a February 2024 article in the Anatolian Journal of Cardiology highlighted research findings where AI and machine learning applications in monitoring heart failure patients led to reduced mortality rates through accurate prognosis predictions. Furthermore, AI-driven risk stratification using sinus rhythm electrocardiograms refines atrial fibrillation (AF) screening initiatives, significantly reducing the number of patients required for screening.
Technological advancements, particularly the integration of artificial intelligence into clinical decision support systems (CDSS), have spurred their adoption in hospitals, fueling the market's growth. For example, in January 2023, Grand River Hospital partnered with Signal 1 to explore an AI-driven CDSS. This system utilizes algorithms developed at St. Michael's Hospital. Such advancements enhance clinician decision-making and facilitate timely patient interventions by predicting changes in patient needs and conditions, further propelling the market's growth.
Furthermore, the rise of artificial intelligence technology has spurred the development of sophisticated clinical decision-support tools. This advancement has seen heightened adoption rates in hospitals and clinics, propelling the market's growth. For instance, in February 2023, Apollo Hospitals Group introduced its Clinical Intelligence Engine for physicians in India, integrated into the Apollo 24|7 platform. This is developed using artificial intelligence (AI) and machine learning (ML) techniques, and it enhances diagnostic accuracy, boosts physician productivity, and prioritizes patient satisfaction.
Therefore, owing to the rising adoption of AI-powered CDS systems across healthcare facilities, in the diagnosis of cardiovascular diseases among patients, and the growing development of AI-CDS systems, the studied market is expected to grow during the forecast period. However, data privacy, ethical considerations, and a lack of skilled professionals are likely to impede the market's growth during the forecast period.
AI-Powered Clinical Decision Support Market Trends
The Medical Diagnosis Segment is Expected to Witness Significant Growth During the Forecast Period
AI-powered clinical decision support systems in medical diagnosis use artificial intelligence technologies to assist healthcare professionals in identifying, diagnosing, and managing medical conditions. These systems aim to enhance diagnostic accuracy and efficiency by analyzing vast amounts of medical data.
Factors such as the rising burden of chronic and infectious diseases among the population propelling the demand for early diagnosis and advanced treatments, increasing demand for personalized medicines, and technological advancements are expected to boost the segment's growth during the forecast period.
The rising burden of chronic diseases such as cancer among the population propels the need for early diagnosis and therapeutics, which is anticipated to propel the segment's growth. For instance, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2024, approximately 286,664 new cancer cases are expected to be diagnosed in Spain in 2024 compared to 279,260 new cases of cancer diagnosed in Spain in 2023. AI-powered clinical decision support is increasingly being utilized in cancer care to enhance diagnosis, treatment, planning, and patient management, hence anticipated to drive the segment's growth during the forecast period.
Artificial intelligence (AI) has found extensive applications across various medical domains, including image diagnosis, pathological classification, treatment selection, and prognosis analysis. Numerous studies have evaluated the efficacy of AI-driven Clinical Decision Support (CDS) systems in diagnosing cancer in patients. For instance, a January 2023 article in the International Journal of Medical Sciences highlighted that AI-based CDS systems play a pivotal role in suggesting tumor treatments, particularly in hospitals with limited access to expert resources.
Similarly, an article published in Infection and Drug Resistance in July 2024 highlighted the capabilities of AI-CDSS in enhancing clinical decision-making. Specifically, AI-CDSS provides clinicians with real-time, data-driven insights, especially in treating infections from carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. The system rapidly decodes intricate diagnostic data, suggests tailored treatment plans, and forecasts potential resistance trends. This streamlines diagnostics and promotes a focused approach to antibiotic therapy. Thus, the introduction of AI-CDSS underscores the commitment to harnessing cutting-edge technology to combat antibiotic resistance, marking a significant step in improving clinical outcomes and promoting responsible antibiotic use.
Therefore, the high burden of cancer, coupled with the increasing utilization of AI-powered CDSS in the diagnosis of various diseases, the segment is anticipated to witness significant growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
Factors such as the rising prevalence of diseases, increasing incidents of medical errors, the growing complexity of healthcare in the country, government initiatives to improve patient outcomes, technological advancements, and focus on cost-effectiveness are expected to boost the market's growth.
The increasing burden of chronic diseases among the population is the key factor driving the market's growth. For instance, according to 2024 updated data published by the International Diabetes Federation, about 17 million people are expected to suffer from diabetes in Mexico, and this number is projected to reach 21 million by 2045. Hence, AI-powered CDSS can assist healthcare professionals in managing these complex conditions by providing decision support for diagnosis, treatment options, medication management, and preventive care, contributing to better outcomes for patients with chronic diseases.
Furthermore, the development of a technologically advanced clinical decision support system for accelerating disease diagnosis is expected to surge the market growth over the forecast period. For instance, in July 2024, DIGITAL, Canada's Global Innovation Cluster for digital technologies, made its largest investment in collaboration with pioneering Canadian health tech companies and researchers, aiming to propel the development and implementation of AI-driven technologies. These advancements are designed to bolster support for healthcare providers and improve patient outcomes. Through its investment in the Health Compass II project, DIGITAL is set to roll out a cutting-edge suite of four AI-driven modules. These modules are crafted to boost patient engagement, alleviate administrative burnout, aid healthcare professionals in documentation, and refine clinical decision-making.
Similarly, in January 2023, VisualDx received a grant from the Bill & Melinda Gates Foundation to develop diagnostic and surveillance tools to help medical providers improve treatment decisions and outcomes in underserved areas. VisualDx expanded equitable access to its clinical decision support, artificial intelligence (AI), and machine learning (ML) tools to provide guidance, specialist knowledge, and education for providers in low-resource settings.
Moreover, increasing government initiatives to integrate AI-driven clinical decision support systems into medical device regulations are expected to boost their adoption in medical diagnostics and treatment strategies. For instance, in September 2022, the Food and Drug Administration issued new guidance indicating that certain AI tools warrant regulation as medical devices, reinforcing the agency's oversight of clinical decision support (CDS) software. This guidance enumerates specific AI tools, such as those predicting sepsis, predicting future heart failure, and detecting potential opioid addiction, that should be classified and regulated as medical devices.
Therefore, owing to the high burden of cancer and diabetes, technological advancement in CDS systems, and government initiatives, the studied market is expected to grow during the forecast period.
AI-Powered Clinical Decision Support Industry Overview
The market for AI-powered clinical decision support is semi-consolidated owing to the presence of a large number of players and entrants of new players in the market. Key players are adopting key strategic activities such as collaborations, partnerships, and product launches to expand their product portfolio and retain their market share. Some of the key companies in the market are Change Healthcare, Elsevier Health, IQVIA, Signal 1, and WELL Health Technologies Corp.
AI-Powered Clinical Decision Support Market Leaders
-
Change Healthcare
-
Elsevier Health
-
IQVIA
-
Signal 1
-
WELL Health Technologies Corp.
- *Disclaimer: Major Players sorted in no particular order
AI-Powered Clinical Decision Support Market News
- May 2024: WELL Health Technologies Corp. launched HEALWELL AI, a second-generation WELL AI Decision Support (WAIDS). The upgraded WAIDS includes screening capabilities for numerous chronic diseases such as chronic kidney disease, hypertension, and diabetes, enabling risk stratification of patients into high-, medium-, or low-risk categories. This expansion broadens WAIDS's utility in detecting more than 100 rare and chronic diseases, providing clinically validated insights that identify care gaps and equip clinicians with actionable information at the point of care.
- February 2024: Elsevier Health, in partnership with OpenEvidence, launched ClinicalKey AI, the first and most advanced clinical decision support tool in the United States that combines the latest and most trusted medical content with generative artificial intelligence (AI) to help clinicians at the point of care.
AI-Powered Clinical Decision Support Industry Segmentation
As per the scope of the report, AI-powered clinical decision support utilizes artificial intelligence technologies to aid healthcare providers in their clinical decision-making. By employing techniques like machine learning, natural language processing, and data analytics, these systems scrutinize patient data, offering recommendations and insights that enhance patient care. Consequently, AI clinical decision support systems play a pivotal role in refining the diagnosis, treatment, and prognosis of medical conditions.
The AI-powered clinical decision support market is segmented by component, deployment mode, application, end user, and geography. By component, the market is segmented by software and services. By deployment mode, the market is segmented into cloud-based and on-premise. By application, the market is segmented by medical diagnosis, treatment planning, patient monitoring, alerts, reminders, and risk prediction, and prescription decision support and personalized medicine. By end user, the market is segmented by hospitals/clinics, research academics, and pharmaceutical and biotechnology companies. By geography, the market is divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The market provides the value (USD) for the above-mentioned segments.
| By Component | Software | ||
| Services | |||
| By Deployment Mode | Cloud-based | ||
| On-premise | |||
| By Application | Medical Diagnosis | ||
| Treatment Planning | |||
| Patient Monitoring | |||
| Alerts, Reminders, and Risk Prediction | |||
| Prescription Decision Support and Personalized Medicine | |||
| Be End User | Hospitals/Clinics | ||
| Research Academics/Institutes | |||
| Pharmaceutical and Biotechnology Companies | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Software |
| Services |
| Cloud-based |
| On-premise |
| Medical Diagnosis |
| Treatment Planning |
| Patient Monitoring |
| Alerts, Reminders, and Risk Prediction |
| Prescription Decision Support and Personalized Medicine |
| Hospitals/Clinics |
| Research Academics/Institutes |
| Pharmaceutical and Biotechnology Companies |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
AI-Powered Clinical Decision Support Market Research FAQs
How big is the AI-Powered Clinical Decision Support Market?
The AI-Powered Clinical Decision Support Market size is expected to reach USD 0.87 billion in 2025 and grow at a CAGR of 15.60% to reach USD 1.79 billion by 2030.
What is the current AI-Powered Clinical Decision Support Market size?
In 2025, the AI-Powered Clinical Decision Support Market size is expected to reach USD 0.87 billion.
Who are the key players in AI-Powered Clinical Decision Support Market?
Change Healthcare, Elsevier Health, IQVIA, Signal 1 and WELL Health Technologies Corp. are the major companies operating in the AI-Powered Clinical Decision Support Market.
Which is the fastest growing region in AI-Powered Clinical Decision Support Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in AI-Powered Clinical Decision Support Market?
In 2025, the North America accounts for the largest market share in AI-Powered Clinical Decision Support Market.
What years does this AI-Powered Clinical Decision Support Market cover, and what was the market size in 2024?
In 2024, the AI-Powered Clinical Decision Support Market size was estimated at USD 0.73 billion. The report covers the AI-Powered Clinical Decision Support Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the AI-Powered Clinical Decision Support Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
AI-Powered Clinical Decision Support Industry Report
Statistics for the 2025 AI-Powered Clinical Decision Support market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. AI-Powered Clinical Decision Support analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
